A detailed history of Ubs Asset Management Americas Inc transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 113,635 shares of SWTX stock, worth $3.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
113,635
Previous 70,761 60.59%
Holding current value
$3.64 Million
Previous $3.48 Million 22.92%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$36.06 - $47.62 $1.55 Million - $2.04 Million
42,874 Added 60.59%
113,635 $4.28 Million
Q1 2024

May 15, 2024

BUY
$36.5 - $52.5 $45,552 - $65,520
1,248 Added 1.8%
70,761 $3.48 Million
Q4 2023

Feb 14, 2024

BUY
$18.94 - $37.24 $275,520 - $541,730
14,547 Added 26.47%
69,513 $2.54 Million
Q3 2023

Nov 13, 2023

BUY
$23.12 - $31.38 $285,208 - $387,103
12,336 Added 28.94%
54,966 $1.27 Million
Q1 2023

May 15, 2023

BUY
$24.97 - $34.05 $392,328 - $534,993
15,712 Added 58.37%
42,630 $1.1 Million
Q4 2022

Feb 14, 2023

BUY
$21.73 - $28.72 $62,951 - $83,201
2,897 Added 12.06%
26,918 $700,000
Q3 2022

Nov 14, 2022

BUY
$24.1 - $39.66 $195,523 - $321,761
8,113 Added 51.0%
24,021 $685,000
Q2 2022

Aug 12, 2022

SELL
$18.36 - $60.07 $91,891 - $300,650
-5,005 Reduced 23.93%
15,908 $391,000
Q2 2021

Aug 16, 2021

BUY
$67.45 - $85.63 $102,051 - $129,558
1,513 Added 7.8%
20,913 $1.72 Million
Q1 2021

May 14, 2021

BUY
$65.1 - $93.59 $247,379 - $355,642
3,800 Added 24.36%
19,400 $1.43 Million
Q4 2020

Mar 01, 2021

BUY
$48.36 - $77.92 $251,472 - $405,184
5,200 Added 50.0%
15,600 $1.13 Million
Q3 2020

Nov 13, 2020

BUY
$36.14 - $51.99 $375,856 - $540,696
10,400 New
10,400 $495,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.